FNIH’s David Wholley

What $34,000 per Patient Buys in Lung-MAP

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Cancer Letter asked David Wholley, director of the Foundation for the National Institutes of Health Biomarker Consortium, to explain the novel scientific and administrative structure of Lung-MAP.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe

YOU MAY BE INTERESTED IN

U.S. Deputy Secretary for Health and Human Services, Andrea Palm, and Sweden's Minister for Health Care, Acko Ankarberg Johansson, signing the agreement. Credit: Joel Apelthun/Government Offices of SwedenThe United States and Sweden signed an agreement to step up collaborations in science and technology by focusing on cancer research.
Paul Goldberg
Editor & Publisher

Login